TG Therapeutics Inc (NASDAQ:TGTX) traded at $38.85 at last check on current trade day and made an upward move of 1.07% on its previous day’s price.
Analysts tracking the company’s growth have also given it a consensus growth in revenue estimated at 117.32M, with a low of 114.6M and a high of 119.9M. The median projection represents growth squeezing down to 84.84% compared to sales growth for the corresponding quarter a year ago. According to analyst consensus estimates figures, the company’s yearly revenue forecast for current year is expected to hit 557.45M, or 69.43% up from figures reported last year.
On the other hand, looking at the outlook for the TGTX stock, short term indicators assign the stock an average of 100% Buy, while medium term indicators assign it an average of 100% Buy.
Based on estimates by 6 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 1 have rated the TG Therapeutics Inc (TGTX) stock as a Hold, while 5 rate it as a Buy. 0 analyst(s) rate it as overweight while 0 of them rated it as underweight, whereas 0 suggest the stock as a Sell. The stock has an overall rating of Buy and investors could take advantage and scoop up stock of the company.
Looking further, we note that the PEG ratio for the TGTX stock currently stands at 1.78, and the most recent price level today is 20.74% off its SMA20 and 23.61% from its 50-day simple moving average. The RSI (14) is pointing at 74.00 while the volatility over the past week is 10.76% and jumps to 5.96% over the past one month. The beta value is 2.25, while the average true range (ATR) is currently pointing at 2.04. The average price target for the stock over the next 12 months is $27.5, with the estimates having a low of $27.5 and a high of $27.5. These price ends are 29.21% and 29.21% off the today’s price level respectively, although investors could be excited at the prospect of a 29.21% if the TGTX share price touches on the median price of $27.5.
